Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated

Optimizing SG&A Costs: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Intra-Cellular Therapies, Inc. and Corcept Therapeutics Incorporated have taken different paths in optimizing these costs. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. Meanwhile, Corcept Therapeutics experienced a more moderate rise, with expenses increasing by approximately 5 times over the same period.

This divergence highlights contrasting strategies: Intra-Cellular Therapies may be investing heavily in growth and expansion, while Corcept Therapeutics appears to be maintaining a more controlled cost structure. As the biotech industry continues to evolve, these strategies will play a pivotal role in shaping each company's future success.